Thalidomide-O-amido-C3-COOH is primarily utilized in the development of targeted cancer therapies. It functions as a linker molecule in antibody-drug conjugates (ADCs), enabling the precise delivery of cytotoxic agents to cancer cells while minimizing damage to healthy tissues. This compound is also explored in proteolysis-targeting chimeras (PROTACs) to degrade specific disease-causing proteins, offering potential in treating conditions like cancer and neurodegenerative disorders. Its application in drug design highlights its role in enhancing therapeutic efficacy and reducing off-target effects.